menu
    • menu

    Company profile for Jubilant Therapeutics

    NEW Drugs in Dev.: 5
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U....
    Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Jubilant TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1430 Route 206, Suite 110 Bedminster, NJ 07921
    Telephone
    Telephone
    +1 267-888-4319
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.jubilanttx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/jubilant-therapeutics-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Jubilant Radiopharma & Simplified Imaging Announce Partnership
    Jubilant Radiopharma & Simplified Imaging Announce Partnership

    30 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241030983546/en

    BUSINESSWIRE
    30 Oct 2024
    Share Share
    Jubilant announces first patient dosing in global clinical trials
    Jubilant announces first patient dosing in global clinical trials

    25 Oct 2024

    // FINANCIALXPRESS

    https://www.financialexpress.com/business/healthcare-jubilant-therapeutics-inc-announces-first-patient-dosing-in-global-clinical-trials-3649433/

    FINANCIALXPRESS
    25 Oct 2024
    Share Share
    JBI-802 initial Phase I data suggests potential in sensitizing immunotherapy resistant tumors
    JBI-802 initial Phase I data suggests potential in sensitizing immunotherapy resistant tumors

    08 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jbi-802-initial-phase-i-data-suggests-therapeutic-potential-in-sensitizing-immunotherapy-resistant-tumors-and-in-myeloproliferative-neoplasms-with-thrombocytosis-302028480.html

    PR NEWSWIRE
    08 Jan 2024
    Share Share
    Jubilant Appoints Nadir Patel as an Independent Member of Its Board of Directors
    Jubilant Appoints Nadir Patel as an Independent Member of Its Board of Directors

    15 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jubilant-therapeutics-inc-appoints-nadir-patel-as-an-independent-member-of-its-board-of-directors-301852053.html

    PR NEWSWIRE
    15 Jun 2023
    Share Share
    Jubilant's Selective Demonstrates Activity in Rheumatoid Arthritis Models
    Jubilant's Selective Demonstrates Activity in Rheumatoid Arthritis Models

    13 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jubilant-therapeutics-incs-selective-orally-administered-pad4-inhibitor-demonstrates-activity-in-rheumatoid-arthritis-preclinical-models-301796864.html

    PR NEWSWIRE
    13 Apr 2023
    Share Share
    Jubilant receives Orphan Drug Designation for the PRMT5 inhibitor
    Jubilant receives Orphan Drug Designation for the PRMT5 inhibitor

    13 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jubilant-therapeutics-inc-receives-orphan-drug-designation-for-the-prmt5-inhibitor---jbi-778-for-the-treatment-of-glioblastoma-multiforme-gbm-301745105.html

    PR NEWSWIRE
    13 Feb 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search